Page 2 - Natco Pharma

Sensex leaps 1,163 pts from the day's low, ends 581 pts up; Nifty tops 16K

CLOSING BELL: The winners included Indian Oil Corporation, Sun Pharma, Tata Consumer Products, TCS, Cipla, Shree Cement, NTPC, Tech M, Dr Reddy's Labs, Wipro, Ultratech Cement, and Infosys

Here's why HDFC Securities recommends buying VRL Logistics, Natco Pharma

Logistics stocks have been showing strength on the medium term charts, according to Vinay Rajani of HDFC Securities.

Natco board approves proposal to acquire US-based pharma company

The company's board has approved to acquire Dash Pharmaceuticals through one of its subsidiary units, it said

Natco Pharma launches novel drug for colorectal, gastric cancer

Natco Pharma on Thursday said it has launched a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorectal and gastric cancer, in the country. The company has launched the product under the brand name Tipanat in a pack of 20 tablets in a bottle, Natco Pharma said in a regulatory filing. Tipanat is a novel antineoplastic nucleoside analog indicated for the treatment of advanced colorectal and gastric cancer. In India, around 1,25,000 new cases of the above-mentioned cancers are reported every year. Tipanat is of high importance in not only extending survival but also in preserving the quality of life in the late lines of treatment which is currently an unmet medical need, the drug maker said. The company said it has launched the medication at an affordable price.

Dr Reddy's, Natco Pharma launch generic cancer drug in Canada

Dr Reddy's Laboratories and Natco Pharma on Thursday said they have launched generic capsules used in the treatment of multiple myeloma and myelodysplastic syndrome patients in the Canadian market.

Natco Pharma slips 6% as Delhi HC allows injunction application by FMC Corp

The Hon'ble High Court of Delhi today orally pronounced judgment in the interim injunction application filed by FMC Corporation on CTPR

Natco Pharma surges 20%, hits new high on USFDA nod for cancer drug

The company has received approval from the US health regulator for the generic version of Celgene's multiple myeloma drug, Revlimid (Lenalidomide) capsules in the US

Natco gets approval for emergency use of Baricitinib for Covid-19 treatment

Natco Pharma has received emergency use approval for Baricitinib tablets, for the treatment of Covid-19 positive patients, from the Central Drugs Standard Control Organization (CDSCO) in India

Natco Pharma gains 4% on emergency use approval for Covid-19 medicine

The company has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India

Natco Pharma rallies 7% as firm seeks nod for Covid medicine Molnupiravir

Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of Covid-19 replication

Covid: Natco Pharma seeks approval for Molnupiravir capsules phase 3 trials

Natco Pharma Limited on Monday said it applied to the Central Drugs Standard Control Organisation (CDSCO) for approval of Phase-III clinical trial of Molnupiravir Capsules

Natco Pharma's board approves acquiring 1% in its Canadian subsidiary

Drug major Natco Pharma on Friday said its board has approved acquiring about 1 per cent stake in its Canadian subsidiary

Natco Pharma Q2 net profit rises 73% to Rs 204 crore on robust sales

Consolidated total income of the company stood at Rs 827.9 crore for the quarter under consideration

Multiple growth catalysts falling in place for Natco Pharma: Analysts

Strong impetus to exports by a mega product launch in North America and business outside the US bode well for earnings

Natco Pharma eyes launch of 8-10 new drugs yearly in Indian market

Natco Pharma aims to launch around 10 new products every year in the Indian market, the city-based drug maker said on Thursday

Natco Pharma reports 14.5% decline in net profit at Rs 122 cr for Q1

The company had posted a net profit of Rs 142.8 crore for the corresponding period of the previous fiscal

Stock picks by Sameet Chavan of Angel Broking: Buy Natco Pharma, IRB Infra

The entire pharma space has been in limelight since the coronavirus pandemic outbreak

Natco Pharma Q4 PBT down 23% at Rs 117 cr on decline in Hep C portfolio

Total income for the quarter down marginally to Rs 477.2 cr; full-year pre-tax at Rs 569 cr

Taiho Pharma moves US court against Natco for patent infringement

Taiho alleged that the Indian drug maker's proposed generic Lonsurf (trifluridine and tipiracil) will infringe the patent

Huge relief for cardio-diabetic patients as three key drugs go off patent

The prices have already dropped by almost 80% in most cases.